ArticleClinical epigenetics2018
The signature of liver cancer in immune cells DNA methylation.
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 69 citations in OpenAlex.
- Peripheral blood mononuclear cell DNA methylation signatures guide surgical decision-making in indeterminate pulmonary nodules.Communications medicine · 2026Article
- Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients.bioRxiv : the preprint server for biology · 2026Article
- T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy.Journal of cellular and molecular medicine · 2026Review
- Putative Imprinting Control Regions with Aberrant Blood-Based DNA Methylation are Associated with Hepatocellular Carcinoma Risk.Journal of hepatocellular carcinoma · 2026Article
- Dynamics of peripheral immune signature identified by multi-omics and its impact on recurrence after radiofrequency ablation of hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Peripheral blood mononuclear cell DNA methylation biomarkers for prognostic stratification in Chinese lung adenocarcinoma: a genome-wide epigenetic profiling study.Clinical epigenetics · 2025Article
- The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients.The oncologist · 2025Article
- EpipwR: efficient power analysis for EWAS with continuous outcomes.Bioinformatics advances · 2025Article
- DNA methylation analysis of peripheral blood mononuclear cells in diagnosing breast cancer from benign breast lesions.Journal of translational medicine · 2024Article
- Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.Clinical and translational medicine · 2024Review
- Clinical validation of peripheral blood mononuclear cell DNA methylation markers for accurate early detection of hepatocellular carcinoma in Asian patients.Communications medicine · 2024Article
- The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia.International immunopharmacology · 2024Article
- Investigating FGFR2 gene as a blood-based epigenetic biomarker in gastric cancer.Molecular biology reports · 2024Article
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer.Nature communications · 2023Article
- Article
- Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.Oncogene · 2023Review
- The current status and future of PD-L1 in liver cancer.Frontiers in immunology · 2023Review
- F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Background: The idea that changes to the host immune system are critical for cancer progression was proposed a century ago and recently regained experimental support. Results: Herein, the hypothesis that hepatocellular carcinoma (HCC) leaves a molecular signature in the host peripheral immune system was tested by profiling DNA methylation in peripheral blood mononuclear cells (PBMC) and T cells from a discovery cohort ( Conclusions: The study reveals a broad signature of hepatocellular carcinoma in PBMC and T cells DNA methylation which discriminates early HCC stage from chronic hepatitis B and C and healthy controls, intensifies with progression of HCC, and is highly enriched in immune function-related genes such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.